ClinicalTrials.gg
Status unknownNCT04920721Updated Jun 10, 2021

Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy

An observational study in Drug Allergy, sponsored by Central Hospital, Nancy, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Central Hospital, Nancy, France · Observational

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
62
Ages
18 Years and older
Sex
All
01

Study summary

To assess the efficacy of skin tests with platinum salts in patients suspects with immediate hypersensitivity reactions.

All patients adressed in consultation to the Allergy Department of university hospital of nancy for an immediate hypersensitivity reaction to platinum salts between 2015 and 2021 were retrospectively recruited.

02

Conditions studied

  • Drug Allergy

Keywords

  • immediate hypersensitivity
  • platinum salts
  • skin tests
  • tolerance induction
03

In context

Drug Hypersensitivity

57 studies on the registry are indexed under Drug Hypersensitivity; 18 are open to participants now.

This study's planned enrollment of 62 is below the median of 204 across 30 observational studies indexed under Drug Hypersensitivity.

Browse Drug Hypersensitivity studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with suspected immediate hypersensitivity reactions to platinum salts

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult
  • suspected immediate reaction to platinum salts

Exclusion criteria

Exclusion Criteria:

  • skin tests not achievable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
62 participants (estimated)
Patient registry
No

Groups and cohorts

  • Allergic

    suspected of immediate hypersensitivity reaction to platinum salts with positiv skin tests

    Other: no intervention

  • Non allergic

    suspected of immediate hypersensitivity reaction to platinum salts with negativ skin tests

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention descriptiv study

06

What researchers measure

Primary outcomes

  1. Result of skin test

    prick test and if negativ =\> intradermoreaction

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • CHRU Nancy
    Nancy, Vandoeuvre-Lès-Nancy 54500, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04920721
Responsible party
ADAM Tania (Dr, Central Hospital, Nancy, France) — Principal investigator
First posted
Jun 10, 2021
Start date
Jun 2021 (estimated)
Primary completion
Jul 2021 (estimated)
Completion
Jul 2021 (estimated)
Last update
Jun 10, 2021

Study contacts

Tania ADAM, Dr
Contact
t.adam@chru-nancy.fr
Claudie Mouton-Faivre, Dr
Contact
c.mouton@chru-nancy.fr
Tania ADAM, Dr
principal investigator · CHRU Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion